MapLight Therapeutics, Inc.

NASDAQ:MPLT

Biotechnology

Healthcare
$6.65 +3.11%

+$0.39 today

Market cap
$283.41M
Beta
2.65
P/E (TTM)
-2.8
EPS (TTM)
-$4.41
52W Low $9.10High $40.43

Volume 0.42M

Average 0.73M

MPLT Other Stockholders Equity

Equity items not reported separately, such as additional paid-in capital or treasury stock.

MapLight Therapeutics, Inc.NASDAQ: MPLT

Other Stockholders Equity · Q1 FY2026 · quarter ended Mar 2026

Other stockholders equity remains negative

Q1 FY2026 other stockholders equity was $0, compared with $0 a year earlier.

Context

  • Other stockholders equity amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Other stockholders equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Other Stockholders Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Stockholders Equity history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Stockholders Equity vs competitors

How MPLT compares with its peers on the latest reported figures

  • MPLT's Mar 2026 other stockholders equity of $0 is the highest of the 11 companies compared; the peer median is $0.
  • Other stockholders equity amounts to 0.0% of total assets for MPLT, versus a peer median of 0.0%.
MPLT Competitors Peer median
Other Stockholders Equity for MPLT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MPLTMapLight Therapeutics, Inc.Mar 2026$0 ——0.0%
DFTXDefinium Therapeutics, Inc.Sep 2026$0 ——0.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$0 -100.0%—0.0%
GHRSGH Research PLCMar 2026$0 +100.0%—0.0%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
ANROAlto Neuroscience, Inc.Mar 2026$0 ——0.0%
ZVRAZevra Therapeutics, Inc.Mar 2026$0 ——0.0%
OVIDOvid Therapeutics Inc.Mar 2026$0 -100.0%—0.0%
NERVMinerva Neurosciences, Inc.Jun 2026$0 ——0.0%
AVXLAnavex Life Sciences Corp.Dec 2025$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding MPLT) $0-100.0%—0.0%

Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.67M79.77M38.25M46.73M
Short-term Investments0070.54M258.37M
Net Receivables0000
Inventory0000
Other Current Assets4.37M0019.57M
Total Current Assets32.03M83.6M114.6M324.67M
Property, Plant & Equipment (Net)7.12M6.59M7.56M6.58M
Goodwill0000
Intangible Assets0000
Long-term Investments234K1.22M11.59M148.2M
Tax Assets0000
Other Non-current Assets234K234K3.17M59K
Total Non-current Assets7.36M7.81M22.31M154.84M
Total Assets39.39M91.41M136.92M479.51M
Account Payables3.6M3.25M1.91M0
Short-term Debt348K495K778K891K
Tax Payables0000
Deferred Revenue5.86M4.2M3.24M0
Other Current Liabilities1.34M4M5.98M9.18M
Total Current Liabilities12.6M14.7M15.92M16.23M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities0000
Total Non-current Liabilities5.92M5.43M5.8M4.91M
Total Liabilities18.52M20.13M21.72M21.14M
Common Stock0005K
Retained Earnings(66.08M)(121.79M)(199.37M)(360.52M)
Accumulated OCI00163K(228K)
Other Stockholders Equity(1)000
Minority Interest0000
Total Equity20.87M71.28M115.2M458.37M
Total Debt6.27M5.92M6.58M5.8M
Net Debt(21.39M)(73.85M)(31.67M)(40.93M)

MapLight Therapeutics, Inc.

NASDAQ:MPLT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.